Micafungina Teva

Micafungin, the active ingredient in Micafungina Teva, is an echinocandin presented as an intravenous solution for intravenous use. It is employed to treat invasive candidiasis and other serious Candida infections in immunocompromised patients, including those undergoing transplantation or intensive care.

GNH USA supplies Micafungina Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide. The company ensures quality compliance with EU standards and provides reliable global logistics.

Micafungin is indicated for several serious fungal infections caused by Candida species.

- Invasive candidiasis: treatment of bloodstream and deep‑tissue Candida infections in adults. - Esophageal candidiasis: eradication of Candida lesions in the esophagus. - Prophylaxis in hematopoietic stem cell transplantation: prevention of Candida infection in transplant recipients. - Candida peritonitis and intra‑abdominal infections: therapy for intra‑abdominal Candida contamination.

Micafungin may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Fever: transient elevation of body temperature during infusion. - Nausea: mild to moderate upset stomach. - Headache: occasional mild headache. - Infusion‑related reactions: erythema, flushing, or mild hypotension. - Elevated liver enzymes: transient increase in ALT/AST. - Rash: mild skin erythema.

Serious or Rare Side Effects: - Hepatic failure: severe liver injury requiring monitoring. - Severe hypersensitivity: anaphylaxis or angioedema. - Renal impairment: acute kidney injury in susceptible patients. - Neutropenia: marked reduction in neutrophil count. - Severe hypotension: marked drop in blood pressure during infusion.

Before initiating therapy, clinicians should consider patient‑specific factors and monitor for potential complications.

- Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic dysfunction: assess liver enzymes before and during treatment. - Concomitant immunosuppression: watch for additive infection risk. - Pediatric use: safety and efficacy not established; use only if clearly indicated. - Pregnancy and lactation: benefits must outweigh potential risks; data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce micafungin exposure. - Cyclosporine: may increase micafungin plasma concentrations. - Co‑administration with other echinocandins: additive toxicity risk.

Moderate Interactions (Monitor Closely): - Warfarin: monitor INR for possible anticoagulant effect alteration. - Statins (e.g., simvastatin): observe for signs of myopathy. - Immunosuppressants (e.g., tacrolimus): check drug levels regularly.